361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes

• Magnus Jaderberg,
• Victor Levitsky,
• Luis Paz-Ares,
• Lukasz Kuryk,
• Nicolas Isambert,
• Susana Cedres,
• Xavier Serres,
• Charles Ricordel,
• Santiago Ponce Aix,
• Anne-Sophie Moller,
• Sylvia Vetrhus

Affiliations

Magnus Jaderberg

1Research and Development, Oslo, Norway

Victor Levitsky

1Research and Development, Oslo, Norway

Luis Paz-Ares

2Medical Oncology, Sevilla, Spain

Lukasz Kuryk

1Research and Development, Oslo, Norway

Nicolas Isambert

2Medical Oncology, Sevilla, Spain

Susana Cedres

2Medical Oncology, Sevilla, Spain

Xavier Serres

3Radiology, Barcelona, Spain

Charles Ricordel

4Pulmonology, Rennes, France

Santiago Ponce Aix

2Medical Oncology, Sevilla, Spain

Anne-Sophie Moller

1Research and Development, Oslo, Norway

Sylvia Vetrhus

1Research and Development, Oslo, Norway